Does the media favor EDSA or TNXP?

In the previous week, Edesa Biotech had 12 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 15 mentions for Edesa Biotech and 3 mentions for Tonix Pharmaceuticals. Edesa Biotech's average media sentiment score of 0.06 beat Tonix Pharmaceuticals' score of -0.56 indicating that Edesa Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edesa Biotech 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tonix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Does the media favor EDSA or ARCT?

In the previous week, Edesa Biotech had 11 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 15 mentions for Edesa Biotech and 4 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.97 beat Edesa Biotech's score of 0.06 indicating that Arcturus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edesa Biotech 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcturus Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is KRRO or EDSA more profitable?

Edesa Biotech has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Korro Bio's return on equity of -114.26% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Korro Bio -1,834.48% -114.26% -68.57% Edesa Biotech N/A -560.22% -105.74%

Does the media prefer KRRO or EDSA?

In the previous week, Edesa Biotech had 7 more articles in the media than Korro Bio. MarketBeat recorded 15 mentions for Edesa Biotech and 8 mentions for Korro Bio. Korro Bio's average media sentiment score of 0.27 beat Edesa Biotech's score of 0.06 indicating that Korro Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Korro Bio 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edesa Biotech 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IVVD or EDSA more profitable?

Edesa Biotech has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Invivyd's return on equity of -59.73% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Invivyd -183.90% -59.73% -48.97% Edesa Biotech N/A -560.22% -105.74%

Does the media prefer IVVD or EDSA?

In the previous week, Invivyd had 16 more articles in the media than Edesa Biotech. MarketBeat recorded 31 mentions for Invivyd and 15 mentions for Edesa Biotech. Invivyd's average media sentiment score of 0.24 beat Edesa Biotech's score of 0.06 indicating that Invivyd is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edesa Biotech 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PLX or EDSA?

In the previous week, Edesa Biotech had 7 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 15 mentions for Edesa Biotech and 8 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 0.21 beat Edesa Biotech's score of 0.06 indicating that Protalix BioTherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protalix BioTherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edesa Biotech 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Edesa Biotech (EDSA) Competitors

$4.43 -0.33 (-6.93%)

As of 08/21/2026 04:00 PM Eastern

Compare

EDSA vs. TNXP, ARCT, KRRO, IVVD, and PLX

Should you buy Edesa Biotech stock or one of its competitors? Edesa Biotech's main competitors and comparable companies include Tonix Pharmaceuticals (TNXP), Arcturus Therapeutics (ARCT), Korro Bio (KRRO), Invivyd (IVVD), and Protalix BioTherapeutics (PLX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Edesa Biotech compare to Tonix Pharmaceuticals?

Edesa Biotech (NASDAQ:EDSA) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

In the previous week, Edesa Biotech had 12 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 15 mentions for Edesa Biotech and 3 mentions for Tonix Pharmaceuticals. Edesa Biotech's average media sentiment score of 0.06 beat Tonix Pharmaceuticals' score of -0.56 indicating that Edesa Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edesa Biotech	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tonix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 24.4% of Edesa Biotech shares are owned by insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Edesa Biotech presently has a consensus price target of $5.00, suggesting a potential upside of 12.87%. Tonix Pharmaceuticals has a consensus price target of $24.50, suggesting a potential upside of 95.22%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

Edesa Biotech has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -548.64%. Tonix Pharmaceuticals' return on equity of -68.99% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-560.22%	-105.74%
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%

Edesa Biotech has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.69, indicating that its share price is 69% more volatile than the broader market.

Edesa Biotech has higher earnings, but lower revenue than Tonix Pharmaceuticals. Edesa Biotech is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.69	N/A
Tonix Pharmaceuticals	$13.11M	16.42	-$124.02M	-$12.94	N/A

Summary

Tonix Pharmaceuticals beats Edesa Biotech on 9 of the 16 factors compared between the two stocks.

How does Edesa Biotech compare to Arcturus Therapeutics?

Edesa Biotech (NASDAQ:EDSA) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

Edesa Biotech has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -317.62%. Arcturus Therapeutics' return on equity of -46.54% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-560.22%	-105.74%
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%

5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 24.4% of Edesa Biotech shares are owned by company insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Edesa Biotech has higher earnings, but lower revenue than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Edesa Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.69	N/A
Arcturus Therapeutics	$82.03M	4.66	-$65.78M	-$3.31	N/A

In the previous week, Edesa Biotech had 11 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 15 mentions for Edesa Biotech and 4 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.97 beat Edesa Biotech's score of 0.06 indicating that Arcturus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edesa Biotech	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcturus Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Edesa Biotech currently has a consensus target price of $5.00, suggesting a potential upside of 12.87%. Arcturus Therapeutics has a consensus target price of $20.00, suggesting a potential upside of 48.70%. Given Arcturus Therapeutics' higher probable upside, analysts plainly believe Arcturus Therapeutics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60

Edesa Biotech has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.39, suggesting that its stock price is 139% more volatile than the broader market.

Summary

Arcturus Therapeutics beats Edesa Biotech on 8 of the 15 factors compared between the two stocks.

How does Edesa Biotech compare to Korro Bio?

Korro Bio (NASDAQ:KRRO) and Edesa Biotech (NASDAQ:EDSA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Edesa Biotech has lower revenue, but higher earnings than Korro Bio. Edesa Biotech is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$2.38M	81.48	-$117.26M	-$10.00	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.69	N/A

Edesa Biotech has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Korro Bio's return on equity of -114.26% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-114.26%	-68.57%
Edesa Biotech	N/A	-560.22%	-105.74%

13.2% of Korro Bio shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 4.8% of Korro Bio shares are owned by company insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Korro Bio has a beta of 3.04, indicating that its stock price is 204% more volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

Korro Bio presently has a consensus target price of $16.71, suggesting a potential upside of 26.82%. Edesa Biotech has a consensus target price of $5.00, suggesting a potential upside of 12.87%. Given Korro Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Korro Bio is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Edesa Biotech had 7 more articles in the media than Korro Bio. MarketBeat recorded 15 mentions for Edesa Biotech and 8 mentions for Korro Bio. Korro Bio's average media sentiment score of 0.27 beat Edesa Biotech's score of 0.06 indicating that Korro Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Korro Bio	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edesa Biotech	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Korro Bio beats Edesa Biotech on 11 of the 16 factors compared between the two stocks.

How does Edesa Biotech compare to Invivyd?

Invivyd (NASDAQ:IVVD) and Edesa Biotech (NASDAQ:EDSA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

Invivyd has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

Invivyd presently has a consensus target price of $8.00, indicating a potential upside of 702.81%. Edesa Biotech has a consensus target price of $5.00, indicating a potential upside of 12.87%. Given Invivyd's higher probable upside, analysts clearly believe Invivyd is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

70.4% of Invivyd shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 12.3% of Invivyd shares are held by company insiders. Comparatively, 24.4% of Edesa Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Edesa Biotech has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Invivyd's return on equity of -59.73% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-183.90%	-59.73%	-48.97%
Edesa Biotech	N/A	-560.22%	-105.74%

In the previous week, Invivyd had 16 more articles in the media than Edesa Biotech. MarketBeat recorded 31 mentions for Invivyd and 15 mentions for Edesa Biotech. Invivyd's average media sentiment score of 0.24 beat Edesa Biotech's score of 0.06 indicating that Invivyd is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invivyd	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edesa Biotech	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Edesa Biotech has lower revenue, but higher earnings than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than Edesa Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	5.50	-$52.49M	-$0.33	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.69	N/A

Summary

Invivyd beats Edesa Biotech on 9 of the 16 factors compared between the two stocks.

How does Edesa Biotech compare to Protalix BioTherapeutics?

Protalix BioTherapeutics (NYSE:PLX) and Edesa Biotech (NASDAQ:EDSA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Protalix BioTherapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 404.20%. Edesa Biotech has a consensus price target of $5.00, suggesting a potential upside of 12.87%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Protalix BioTherapeutics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Edesa Biotech had 7 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 15 mentions for Edesa Biotech and 8 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 0.21 beat Edesa Biotech's score of 0.06 indicating that Protalix BioTherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protalix BioTherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edesa Biotech	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Protalix BioTherapeutics has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market.

Protalix BioTherapeutics has higher revenue and earnings than Edesa Biotech. Edesa Biotech is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$80.62M	2.38	$8.31M	$0.23	10.35
Edesa Biotech	N/A	N/A	-$7.19M	-$1.69	N/A

Edesa Biotech has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Edesa Biotech	N/A	-560.22%	-105.74%

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by insiders. Comparatively, 24.4% of Edesa Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Protalix BioTherapeutics beats Edesa Biotech on 9 of the 15 factors compared between the two stocks.

Get Edesa Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EDSA vs. The Competition

Export

Metric	Edesa Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$42.71M	$4.01B	$7.37B	$12.83B
Dividend Yield	N/A	3.64%	2.53%	10.78%
P/E Ratio	-2.62	11.62	272.33	24.21
Price / Sales	N/A	1,305.37	613.72	90.25
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	9.84	17.38	11.25	6.42
Net Income	-$7.19M	-$22.72M	$3.47B	$348.89M
7 Day Performance	-17.20%	3.29%	2.09%	0.08%
1 Month Performance	-21.73%	8.23%	6.64%	3.88%
1 Year Performance	84.58%	55.05%	25.02%	16.98%

Edesa Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EDSA Edesa Biotech	2.1599 of 5 stars	$4.43 -6.9%	$5.00 +12.9%	+84.6%	$42.71M	N/A	N/A	20	News Coverage Analyst Revision Gap Down
TNXP Tonix Pharmaceuticals	3.6432 of 5 stars	$12.34 -2.0%	$24.50 +98.5%	-67.0%	$200.70M	$13.11M	N/A	50
ARCT Arcturus Therapeutics	1.9043 of 5 stars	$7.52 +6.7%	$24.25 +222.5%	-27.3%	$200.38M	$82.03M	N/A	180	News Coverage
KRRO Korro Bio	3.1248 of 5 stars	$13.32 -1.3%	$16.71 +25.5%	-34.2%	$198.65M	$2.38M	N/A	70	News Coverage Analyst Forecast Insider Trade
IVVD Invivyd	3.535 of 5 stars	$0.69 +2.1%	$8.00 +1,063.6%	+91.6%	$198.30M	$53.43M	N/A	100	News Coverage Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EDSA) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edesa Biotech (EDSA) Competitors

EDSA vs. TNXP, ARCT, KRRO, IVVD, and PLX

How does Edesa Biotech compare to Tonix Pharmaceuticals?

Summary

How does Edesa Biotech compare to Arcturus Therapeutics?

Summary

How does Edesa Biotech compare to Korro Bio?

Summary

How does Edesa Biotech compare to Invivyd?

Summary

How does Edesa Biotech compare to Protalix BioTherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDSA vs. The Competition

Edesa Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Edesa Biotech (EDSA) Competitors

EDSA vs. TNXP, ARCT, KRRO, IVVD, and PLX

How does Edesa Biotech compare to Tonix Pharmaceuticals?

Does the media favor EDSA or TNXP?

Do institutionals and insiders hold more shares of EDSA or TNXP?

Do analysts rate EDSA or TNXP?

Is EDSA or TNXP more profitable?

Which has more risk and volatility, EDSA or TNXP?

Which has stronger earnings and valuation, EDSA or TNXP?

Summary

How does Edesa Biotech compare to Arcturus Therapeutics?

Is EDSA or ARCT more profitable?

Do insiders and institutionals have more ownership in EDSA or ARCT?

Which has better valuation & earnings, EDSA or ARCT?

Does the media favor EDSA or ARCT?

Do analysts prefer EDSA or ARCT?

Which has more risk and volatility, EDSA or ARCT?

Summary

How does Edesa Biotech compare to Korro Bio?

Which has better valuation and earnings, KRRO or EDSA?

Is KRRO or EDSA more profitable?

Do insiders and institutionals have more ownership in KRRO or EDSA?

Which has more volatility & risk, KRRO or EDSA?

Do analysts prefer KRRO or EDSA?

Does the media prefer KRRO or EDSA?

Summary

How does Edesa Biotech compare to Invivyd?

Which has more risk & volatility, IVVD or EDSA?

Do analysts recommend IVVD or EDSA?

Do insiders & institutionals hold more shares of IVVD or EDSA?

Is IVVD or EDSA more profitable?

Does the media prefer IVVD or EDSA?

Which has stronger earnings and valuation, IVVD or EDSA?

Summary

How does Edesa Biotech compare to Protalix BioTherapeutics?

Do analysts prefer PLX or EDSA?

Does the media favor PLX or EDSA?

Which has more volatility & risk, PLX or EDSA?

Which has stronger earnings & valuation, PLX or EDSA?

Is PLX or EDSA more profitable?

Do insiders and institutionals have more ownership in PLX or EDSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDSA vs. The Competition

Edesa Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools